Therapeutic Modulation of T Follicular Helper Cells by Low-Dose IL-2 Treatment.

[1]  A. Ballesteros-Tato,et al.  Mechanisms of action of low-dose IL-2 restoration therapies in SLE. , 2019, Current opinion in immunology.

[2]  L. Graça,et al.  T follicular helper cells and T follicular regulatory cells in rheumatic diseases , 2019, Nature Reviews Rheumatology.

[3]  S. Crotty.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.

[4]  J. Cyster,et al.  B Cell Responses: Cell Interaction Dynamics and Decisions , 2019, Cell.

[5]  R. D. Hatton,et al.  Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells , 2018, Science.

[6]  H. Dumortier,et al.  Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets? , 2016, Journal of immunology research.

[7]  E. Morand,et al.  Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus , 2016, Nature Medicine.

[8]  I. Maclennan,et al.  Follicular Helper T Cells. , 2016, Annual review of immunology.

[9]  A. Sharpe,et al.  T follicular regulatory cells , 2016, Immunological reviews.

[10]  John P. Ray,et al.  The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. , 2015, Immunity.

[11]  D. Klatzmann,et al.  The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases , 2015, Nature Reviews Immunology.

[12]  H. Ueno,et al.  Pathophysiology of T follicular helper cells in humans and mice , 2015, Nature Immunology.

[13]  T. Beddoe,et al.  Efficient production of recombinant IL-21 proteins for pre-clinical studies by a two-step dilution refolding method. , 2013, International immunopharmacology.

[14]  T. Randall,et al.  Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. , 2012, Immunity.

[15]  Jeffrey A. Diamond,et al.  STAT5 is a potent negative regulator of TFH cell differentiation , 2012, The Journal of experimental medicine.

[16]  Mark A. Atkinson,et al.  Central Role for Interleukin-2 in Type 1 Diabetes , 2011, Diabetes.

[17]  J. Bluestone,et al.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells , 2010, The Journal of experimental medicine.

[18]  A. Scheffold,et al.  Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus , 2009, Proceedings of the National Academy of Sciences.